Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
AstraZeneca
Mallinckrodt
Express Scripts

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

NEXPLANON Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Nexplanon patents expire, and when can generic versions of Nexplanon launch?

Nexplanon is a drug marketed by Organon Usa Inc and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-two patent family members in thirty-one countries.

The generic ingredient in NEXPLANON is etonogestrel. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etonogestrel profile page.

Drug patent expirations by year for NEXPLANON
Drug Prices for NEXPLANON

See drug prices for NEXPLANON

Recent Clinical Trials for NEXPLANON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of New MexicoPhase 4
Society of Family PlanningPhase 4
National Institutes of Health (NIH)Phase 4

See all NEXPLANON clinical trials

Pharmacology for NEXPLANON
Drug ClassProgestin
Synonyms for NEXPLANON
(17-alpha)-13-Ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one
(17|A)-13-Ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one
(17alpha)-13-Ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one
(1S,2R,10S,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxy-17-methylidenetetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(8S,9S,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylene-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
048E101
13-Ethyl-11-methylene-18,19-dinor-17-alpha-pregn-4-en-20-yn-3-one
13-Ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
13-Ethyl-17-hydroxy-11-methylidene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one (3-Ketodesogestrel)
165050-21-5
17-Ethinyl-17-beta-hydroxy-18-methyl-11-methylene-4-estren-3-one
17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one
18,19-Dinor-17alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-
18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)-
3-Keto Desogestrel
3-Keto-desogestrel
3-Ketodesogestrel
3-Ketodesogestrel|||3-Oxodesogestrel
3-Oxodesogestrel
3-Oxodesogestrel;3-keto-Desogestrel
304GTH6RNH
54048-10-1
AC1OCEK1
ACN-037292
AKOS030526156
AN-40607
BC252319
BCP28481
BDBM50423516
C-23775
CAS-54048-10-1
CC-28331
CHEBI:50777
CHEMBL1531
CS-2884
D04104
DB00294
Desogestrel Related Compound C, United States Pharmacopeia (USP) Reference Standard
DSSTox_CID_26782
DSSTox_GSID_46782
DSSTox_RID_81900
DTXSID9046782
EINECS 258-936-2
ETONOGESTREL
Etonogestrel (3-Ketodesogestrel)
Etonogestrel (USAN/INN)
Etonogestrel [USAN:INN:BAN]
Etonogestrel, >=98% (HPLC)
Etonogestrel, United States Pharmacopeia (USP) Reference Standard
etonogestrelum
FT-0652914
GTPL7590
HY-B0652
Implanon
Implanon (TN)
MolPort-003-847-336
NCGC00168777-01
ORG 3236
Org-3236
s4673
SCHEMBL117703
Tox21_112638
UNII-304GTH6RNH
ZINC11680067

US Patents and Regulatory Information for NEXPLANON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Organon Usa Inc NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NEXPLANON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0303306 099C0041 Belgium   Start Trial PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306 C980027 Netherlands   Start Trial PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
0303306 29/1999 Austria   Start Trial PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
0303306 SPC/GB99/044 United Kingdom   Start Trial PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Boehringer Ingelheim
Harvard Business School
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.